BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer
Retrieved on:
Tuesday, November 30, 2021
Patient, MEI, Lung, CEO, BUX, Cancer, Technology, Biomarker, Lung cancer, Disease, General manager, Pfizer, Mutation, AstraZeneca, Hospital, Institut universitaire en santé mentale de Montréal, Diagnosis, Partnership, Fluidigm, CSE, Metabolomics, Survival, Research, Genetics, Investor, Risk, OTC Markets Group, Population, Medical director, Artificial intelligence, Efficiency, FSE, LinkedIn, Evaluation, Medical imaging, Pharmaceutical industry
Yohan Boss at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Qubec-Universit Laval - IUCPQ-UL).
Key Points:
- Yohan Boss at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Qubec-Universit Laval - IUCPQ-UL).
- The new screening tools will be combining radiomics, genetics and metabolomics biomarkers who will be integrated using artificial intelligence.
- "When detected early, lung cancer patients have more treatment options and a far greater chance of survival.
- BioMark is developing proprietary, non-invasive, and accurate liquid biopsy-based cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively.